Luminor Capital

Luminor Capital is a private equity group headquartered in Singapore, founded in 2008. The firm focuses on creating value and achieving investment returns by investing in high-growth sectors such as healthcare, resources, consumer, lifestyle, and infrastructure. With offices in Singapore and Beijing, Luminor Capital targets the Asia-Pacific region, where favorable economic conditions and entrepreneurial activity provide attractive business opportunities. The team's core expertise and competence guide their investment strategies, enabling them to capitalize on rewarding projects in this dynamic market.

Foo Fatt Kah

Co-Founder and Managing Director

5 past transactions

Capital C Corporation

Pre Seed Round in 2022
Capital C Corporation is a Singapore-based financial services provider focused on delivering innovative solutions to underserved individuals and businesses. By leveraging financial technology and emerging market trends, the company develops a diverse range of services, including individual loans, business loans, and auto financing. Capital C Corporation employs a unique credit scoring methodology to facilitate accessible and affordable credit, thereby enabling clients to maximize their financial potential. Through its commitment to inclusivity and efficiency, the company aims to bridge the financial gap for those who traditionally face challenges in accessing essential financial services.

PT Adiwisista Finansial Teknologi

Series A in 2021
PT Adiwisista Finansial Teknologi operates in the financial services industry, focusing on leveraging technology to offer innovative solutions. Established in 2018, the company has grown to employ around 50 individuals dedicated to enhancing financial accessibility and efficiency. It has engaged in strategic partnerships, such as with Salvatore Financial for securities issuance and with Bank SMBC Indonesia for loan channeling. It oversees Danai.id, a platform under its umbrella, which has secured operational licensing from Indonesia's Financial Services Authority (OJK). The company's commitment to integrating technology with financial services is evident in its efforts to streamline processes and offer financial products that cater to the evolving needs of its clients.

ayondo

Series C in 2015
ayondo Ltd. is a financial technology company based in Singapore, founded in 2014, that specializes in brokerage and social trading services. With a focus on connecting traders and fostering a community, ayondo provides a platform that enables real-time signal execution, catering to self-directed investors, trading strategy providers, and followers. The company emphasizes transparency, low fees, and efficiency in its services, which are designed to enhance the trading experience. Additionally, ayondo offers tailored solutions for asset managers in the institutional sector and operates a franchise system to extend its reach globally.

ayondo

Series C in 2014
ayondo Ltd. is a financial technology company based in Singapore, founded in 2014, that specializes in brokerage and social trading services. With a focus on connecting traders and fostering a community, ayondo provides a platform that enables real-time signal execution, catering to self-directed investors, trading strategy providers, and followers. The company emphasizes transparency, low fees, and efficiency in its services, which are designed to enhance the trading experience. Additionally, ayondo offers tailored solutions for asset managers in the institutional sector and operates a franchise system to extend its reach globally.

TriReme Medical

Series E in 2012
TriReme Medical, Inc. is a privately held medical device company located in Pleasanton, California, founded in 2005. The company specializes in the development, manufacturing, and distribution of advanced therapeutic technologies aimed at treating complex vascular diseases, particularly coronary artery disease (CAD) and peripheral vascular disease. TriReme Medical focuses on creating innovative stent and balloon therapies tailored for challenging anatomical scenarios, such as bifurcations, addressing significant clinical needs in these areas. By providing physicians with differentiated devices, the company aims to enhance patient outcomes in complex coronary and peripheral interventions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.